These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37588995)

  • 1. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
    Wan Z; Wang Y; Li C; Zheng D
    Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined signatures of G protein-coupled receptor family and immune landscape provide a prognostic and therapeutic biomarker in endometrial carcinoma.
    Chen S; Luo X; Yang B; Zhuang J; Guo J; Zhu Y; Mo J
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14701-14719. PubMed ID: 37584707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
    Chen L; Lin J; Wen Y; Chen Y; Chen CB
    Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
    Pan G; Xie H; Xia Y
    Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
    Li C; Wan Z; Deng Q; Li Z; Wang Y
    Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
    Xing P; Jiang Z; Liu Y
    BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma.
    Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z
    Front Oncol; 2023; 13():1170893. PubMed ID: 37124542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.
    Tang C; Fan Y; Zhu S
    BMC Urol; 2024 Mar; 24(1):69. PubMed ID: 38532369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer.
    Yao Z; Zhang H; Zhang X; Zhang Z; Jie J; Xie K; Li F; Tan W
    Front Genet; 2022; 13():923768. PubMed ID: 36147509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.
    Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
    Cancer Manag Res; 2022; 14():67-88. PubMed ID: 35023971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.